Skip to content
DataLookout
Menu

IMPACT-MACSNCT07361874

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

StatusRecruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Phase changed: Not applicable → Phase 4 Show 5 more changesShow less
    • Eligibility criteria expanded, about 103 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Secondary endpoints: 36 to 56
    • Study description expanded, about 95 words
    • Publications: details revised at 7 of 8 entries
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 1, 2026 to Mar 5, 2026
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Insulin Sensitivity (M-value), mg/kg/min
Timeframe: Baseline to Week 26

Secondary (56)

Change in fasting plasma glucose, mg/dL
Change in hemoglobin A1C, %
Change in fasting insulin, µU/mL
Change in glucagon, pg/mL
Change in c-peptide, nmol/L
Show 51 moreShow less
Change in IGF-1, ng/mL
Change in IGF-II, ng/mL
Change in IGFBP-1, ng/mL
Change in leptin, ng/mL
Change in adiponectin, μg/mL
% of patients with normal dexamethasone suppression test, %
Change in steroid profile, ng/24h
Mean change in systolic BP, mmHg
Mean change in diastolic BP, mmHg
Change in cholesterol, mg/dL
Change in Free Fatty Acids, mmol/L
Change in C-reactive protein, pg/mL
Change in TNF-alpha, pg/mL
Change in Interleukin-1, pg/mL
Change in Interleukin-6, pg/mL
Change in body weight, kg
Change in BMI, kg/m2
Change in waist circumference, cm
Change in fat area, cm2
Change in muscle area, cm2
Change in bone mineral density, mg/cm³
Change in chair rise test, stands/30s
Change in Hand Grip Strength, kg
Change in overall quality of life, score
Change in disease-specific QoL, score
Change in mood, score
Change in cognition, seconds
Change in sleep, score
Change in frailty, score
Change in eating behavior, score
Adverse Events and Serious Adverse Events
Change in Insulin Sensitivity (M-value) at Month 12
Change in post-DST cortisol as a continuous variable
Change in ACTH level
DHEA-S
HDL
LDL
triglycerides
Apo B
Lp(a)
HDL function
cholesterol efflux capacity
Change in total fat area
Change in visceral fat area
Change in subcutaneous fat area
Change in muscle area
Change in muscle:fat ratio
Change in liver fat
Change in pancreatic fat
Change in pancreatic volume
Change in adrenal nodule size

Arms and interventions

Arm 1: Adrenalectomy (MACS)Active comparator

Adults with mild autonomous cortisol secretion (MACS) who are clinically eligible for adrenalectomy undergo unilateral adrenalectomy as part of standard clinical care. Participants complete protocol-specified metabolic, hormonal, cardiometabolic, body composition, physical function, and patient-reported outcome assessments through Week 26. Eligible participants may elect to participate in the Optional Extension Phase, with continued follow-up and repeat outcome assessments through Month 12.

Arm 2: Semaglutide (MACS)Active comparator

Adults with MACS receive semaglutide during the initial 26-week treatment period. Eligible participants who elect to participate in the optional extension phase continue semaglutide treatment and protocol-specified follow-up through Month 12.

Arm 3: Semaglutide (Matched Controls)Active comparator

Matched adults without adrenal tumors receive semaglutide using the same dosing approach as semaglutide-treated participants with MACS. This arm allows comparison of semaglutide responses between individuals with and without MACS. Eligible matched controls may participate in the Optional Extension Phase through Month 12 if their corresponding matched index participant also elects to participate and both remain eligible for continued study participation.

Procedures: Intervention 1: Adrenalectomy

Drugs: Intervention 2: Semaglutide

Sites

1 site in 1 country

  • University of Texas Southwestern Medical CenterDallas, Texas, United States